Literature DB >> 3191939

Plasma and synovial fluid meclofenamic acid concentrations in patients with rheumatoid arthritis of the knee.

J R Koup1, D Thomas, E Tucker, A Black, M Ruderman, J A Dixon, A Kinkel.   

Abstract

We have measured plasma and synovial fluid concentrations of meclofenamic acid at 2, 4, 8, and 12 h during steady-state administration (100 mg three times daily for 4-7 days). Paired plasma and synovial samples were obtained pre-treatment and at one of the above times in twelve patients with a diagnosis of rheumatoid arthritis. In addition, the extent of protein binding of meclofenamic acid was assessed in vitro in the pre-treatment plasma and synovial fluid specimens. Peak total concentrations of 1.73 and 0.86 micrograms.ml-1 were observed in plasma (at 2 h) and synovial fluid (at 4 h) respectively. The extent of protein binding was 99.7 and 99.6% (not significantly different) in plasma and synovial fluid respectively. The results of this study are compared to those from similar reported studies of other nonsteroidal anti-inflamatory compounds.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3191939     DOI: 10.1007/bf00609253

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  11 in total

1.  Simultaneous pharmacokinetics of indomethacin in serum and synovial fluid.

Authors:  H W Emori; G D Champion; R Bluestone; H E Paulus
Journal:  Ann Rheum Dis       Date:  1973-09       Impact factor: 19.103

Review 2.  Antirheumatic drug concentrations in human synovial fluid and synovial tissue. Observations on extravascular pharmacokinetics.

Authors:  W J Wallis; P A Simkin
Journal:  Clin Pharmacokinet       Date:  1983 Nov-Dec       Impact factor: 6.447

3.  Protein binding of non-steroidal anti-inflammatory drugs in plasma and synovial fluid of arthritic patients.

Authors:  S Wanwimolruk; P M Brooks; D J Birkett
Journal:  Br J Clin Pharmacol       Date:  1983-01       Impact factor: 4.335

4.  Meclofenamate sodium is an inhibitor of both the 5-lipoxygenase and cyclooxygenase pathways of the arachidonic acid cascade in vitro.

Authors:  A M Boctor; M Eickholt; T A Pugsley
Journal:  Prostaglandins Leukot Med       Date:  1986-08

5.  Plasma and synovial fluid concentrations of diclofenac sodium and its major hydroxylated metabolites during long-term treatment of rheumatoid arthritis.

Authors:  P D Fowler; M F Shadforth; P R Crook; V A John
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

6.  Tolmetin kinetics and synovial fluid prostaglandin E levels in rheumatoid arthritis.

Authors:  S H Dromgoole; D E Furst; R K Desiraju; R K Nayak; M A Kirschenbaum; H E Paulus
Journal:  Clin Pharmacol Ther       Date:  1982-09       Impact factor: 6.875

7.  Osmosin: its effect on plasma and synovial fluid kinetics of indomethacin.

Authors:  P D Fowler; P T Dawes
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

8.  Plasma and synovial fluid kinetics of flurbiprofen in rheumatoid arthritis.

Authors:  L Aarons; R Salisbury; M Alam-Siddiqi; L Taylor; D M Grennan
Journal:  Br J Clin Pharmacol       Date:  1986-02       Impact factor: 4.335

9.  Ibuprofen kinetics in plasma and synovial fluid of arthritic patients.

Authors:  J M Gallo; E P Gall; W R Gillespie; K S Albert; D Perrier
Journal:  J Clin Pharmacol       Date:  1986-01       Impact factor: 3.126

10.  Performance of a diffusional clearance model for beta-lactam antimicrobial agents as influenced by extravascular protein binding and interstitial fluid kinetics.

Authors:  J C Fleishaker; P J McNamara
Journal:  Antimicrob Agents Chemother       Date:  1985-09       Impact factor: 5.191

View more
  1 in total

Review 1.  Recent findings on the pharmacokinetics of non-steroidal anti-inflammatory drugs in synovial fluid.

Authors:  P Netter; B Bannwarth; M J Royer-Morrot
Journal:  Clin Pharmacokinet       Date:  1989-09       Impact factor: 6.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.